Rare Disease DataMart:

Two (2) highly curated files to strategically analyze at the disease, epidemiology, asset, indication, pipeline and company levels.

 

Cost = $10,000 Pay via PayPal (you will receive an email with a download link following confirmation of payment)

Insights & Perspectives

ADA 2017: Conference At-a-glance
20170609 ADA 2017 vFS.pdf
Adobe Acrobat document [100.6 KB]
Age-related Macular Degeneration (AMD): Patient Treatment Challenges
AMD - Challenges in treatment of patient[...]
Adobe Acrobat document [123.4 KB]
Alzheimer's Disease (AD): Stakeholder Needs
AD Stakeholder Needs.pdf
Adobe Acrobat document [541.5 KB]
Building a Franchise Strategy
20170601 AD Above Brand Strategies vf.p[...]
Adobe Acrobat document [209.6 KB]
CAG Differentiation - Cost Benefit
20170518 CAG Differentiation - Cost Bene[...]
Adobe Acrobat document [104.9 KB]
Case Dissection: Baricitinib for Rheumatoid Arthritis (RA)
Baricitinib Case Dissection vFS.pdf
Adobe Acrobat document [284.0 KB]
Case Dissection: Rare Disease
Rare Disease Case Dissection vFS.pdf
Adobe Acrobat document [272.0 KB]
Huge rise in Phase III abstracts: Will these new therapeutics succeed?
20170528 PIII from ASCO vFS.pdf
Adobe Acrobat document [143.4 KB]
Oncology Clinical Development Snapshot
Oncology Open PII-III.pdf
Adobe Acrobat document [339.9 KB]
PARP Snapshot
20170621 PARP Snapshot vFS.pdf
Adobe Acrobat document [497.5 KB]
Phase II Trial Terminations
20170908 Phase II Terminations WP vF.pdf
Adobe Acrobat document [1.1 MB]
Top Oncology Trends
20170522 State of Oncology - AACR+ASCO+I[...]
Adobe Acrobat document [113.8 KB]
What do Oncologists want?
What do Oncologists want vf.pdf
Adobe Acrobat document [97.4 KB]
What’s Top-of-Mind for Payers
What’s Top-of-Mind for Payers vf.pdf
Adobe Acrobat document [249.0 KB]
Print | Sitemap
© Converge Advisory Group